Objective pressure-strain loop（PSL）

and to evaluate effects of anthracycline-based chemotherapy on LV myocardial function in patients with breast cancer.MethodsThirty breast cancer patients treated by anthracycline-based chemotherapy（breast cancer group）and 30 controls（control group）were recruited.Echocardiography was performed before and after 1

2

3

4

5 chemotherapeutic cycle（T0

T1

T2 T3

T4

T5）.Pulse tissue Doppler imaging（PW-TDI）was used to obtain the peak systolic velocity（S’）at 6 sites of mitral annulus.Speckle tracking imaging（STI）and PSL were used to obtain the LV global longitudinal strain（GLS）

the standard deviations and maximum difference（Tls-SD

Tls-dif）of 18 segments longitudinal strain peak time

global work index（GWI）

global constructive work（GCW）

global waste work（GWW）and global work efficiency（GWE）.The differences of the above parameters between the two groups were compared.Results significance of systolic blood pressure

left ventricular ejection fraction（LVEF）

Tei index

mitral ring TDI parameters

strain parameters and myocardial work parameters in the T0 stage in the breast cancer group.Compared with T0 stage

S’-PostSept

S’-Lat

S’-Ant in stage T4 and T5 in breast cancer group were significantly decreased（all P<0.05）

while there were no significant difference in the rest of TDI parameters.Compared with T0 stage

there was no significant changes of GLS in T1～T3 stage in breast cancer group

while GLS in T4 and T5 stages were significantly decreased

and showed a decreasing trend with the progress of chemotherapy cycle（all P<0.05）.T1 s-SD and T1 s-dis in T4 and T4 stage were increased（all P<0.05）.Compared with T0 stage

there were no significant changes of GWI

GCW

GWW and GWE in T1～T3 stage in breast cancer group

GWI

GCW and GWE in T4 and T5 stages were significantly decreased

and showed a decreasing trend with the progress of chemotherapy cycle（all P<0.05）.GWW in T4 and T5 stages were significantly increased

and showed an increasing trend with the progression of chemotherapy cycle（all P<0.05）.Conclusion patients

which provide a new ultrasound technology for the evaluation of chemotherapy-related cardiac function impairment.